{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:04:27Z","timestamp":1791140667308,"version":"4.1.0"},"reference-count":90,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82172597"],"award-info":[{"award-number":["82172597"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"crossref","award":["LY22H160027"],"award-info":[{"award-number":["LY22H160027"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Bethune Charitable Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Typically associated with solid tumors, hypoxia contributes to tumor angiogenesis and lymphangiogenesis through various molecular mechanisms. Accumulating studies indicate that hypoxia-inducible factor is the key transcription factor coordinating endothelial cells to respond to hypoxia in urological cancers, mainly renal cell carcinoma, prostate cancer, and bladder cancer. Moreover, it has been suggested that tumor hypoxia in tumor microenvironment simultaneously recruits stromal cells to suppress immune activities. This review summarizes the mechanisms by which HIF regulates tumorigenesis and elaborates on the associations between HIF and angiogenesis, lymphangiogenesis, and tumor microenvironment in urological cancers.<\/jats:p>","DOI":"10.1007\/s11033-023-08931-2","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T16:10:49Z","timestamp":1702397449000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["The role of HIF in angiogenesis, lymphangiogenesis, and tumor microenvironment in urological cancers"],"prefix":"10.1007","volume":"51","author":[{"given":"Shen","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyang","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyi","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"8931_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"Cancer J Clin"},{"key":"8931_CR2","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1016\/j.trecan.2016.10.016","volume":"2","author":"L Schito","year":"2016","unstructured":"Schito L, Semenza GL (2016) Hypoxia-inducible factors: Master regulators of Cancer Progression. Trends in Cancer 2:758\u2013770. https:\/\/doi.org\/10.1016\/j.trecan.2016.10.016","journal-title":"Trends in Cancer"},{"key":"8931_CR3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-pathol-012513-104720","volume":"9","author":"GL Semenza","year":"2014","unstructured":"Semenza GL (2014) Oxygen sensing, Hypoxia-Inducible factors, and Disease Pathophysiology. Annu Rev Pathol Mech Dis 9:47\u201371. https:\/\/doi.org\/10.1146\/annurev-pathol-012513-104720","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"8931_CR4","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","volume":"92","author":"GL Wang","year":"1995","unstructured":"Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92:5510\u20135514. https:\/\/doi.org\/10.1073\/pnas.92.12.5510","journal-title":"Proc Natl Acad Sci USA"},{"key":"8931_CR5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1126\/science.1059817","volume":"292","author":"M Ivan","year":"2001","unstructured":"Ivan M, Kondo K, Yang H, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, Kaelin WG Jr (2001) HIF\u03b1 targeted for VHL-Mediated Destruction by Proline Hydroxylation: implications for O 2 sensing. Science 292:464\u2013468. https:\/\/doi.org\/10.1126\/science.1059817","journal-title":"Science"},{"key":"8931_CR6","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1101\/gad.924501","volume":"15","author":"PC Mahon","year":"2001","unstructured":"Mahon PC, Hirota K, Semenza GL (2001) FIH-1: a novel protein that interacts with HIF-1\u03b1 and VHL to mediate repression of HIF-1 transcriptional activity. Nature 15:2675\u20132686. https:\/\/doi.org\/10.1101\/gad.924501","journal-title":"Nature"},{"key":"8931_CR7","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1080\/17460441.2019.1613370","volume":"14","author":"N Albadari","year":"2019","unstructured":"Albadari N, Deng S, Li W (2019) The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy. Expert Opin Drug Discov 14:667\u2013682. https:\/\/doi.org\/10.1080\/17460441.2019.1613370","journal-title":"Expert Opin Drug Discov"},{"key":"8931_CR8","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/35107085","volume":"414","author":"PC Mahon","year":"2001","unstructured":"Mahon PC, Hirota K, Semenza GL, Makino Y, Cao R, Svensson K, Bertilsson G, Asman M, Tanaka H, Cao Y, Berkenstam A, Poellinger L (2001) Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature 414:550\u2013554. https:\/\/doi.org\/10.1038\/35107085","journal-title":"Nature"},{"key":"8931_CR9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.eururo.2015.08.007","volume":"69","author":"J Sch\u00f6del","year":"2016","unstructured":"Sch\u00f6del J, Grampp S, Maher ER, Moch H, Ratcliffe PJ, Russo P, Mole DR (2016) Hypoxia, hypoxia-inducible transcription factors, and Renal Cancer. Eur Urol 69:646\u2013657. https:\/\/doi.org\/10.1016\/j.eururo.2015.08.007","journal-title":"Eur Urol"},{"key":"8931_CR10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nrc3844","volume":"15","author":"L Gossage","year":"2015","unstructured":"Gossage L, Eisen T, Maher ER (2015) VHL, the story of a tumour suppressor gene. Nat Rev Cancer 15:55\u201364. https:\/\/doi.org\/10.1038\/nrc3844","journal-title":"Nat Rev Cancer"},{"key":"8931_CR11","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/ng.2699","volume":"45","author":"Y Sato","year":"2013","unstructured":"Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki H, Nagata Y, Yoshida K, Kon A, Suzuki Y, Chiba K, Tanaka H, Niida A, Fujimoto A, Tsunoda T, Morikawa T, Maeda D, Kume H, Sugano S, Fukayama M, Aburatani H, Sanada M, Miyano S, Homma Y, Ogawa S (2013) Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 45:860\u2013867. https:\/\/doi.org\/10.1038\/ng.2699","journal-title":"Nat Genet"},{"key":"8931_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ccr.2008.10.016","volume":"281","author":"JD Gordan","year":"2022","unstructured":"Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL (2022) HIF-\u03b1 effects on c-Myc Distinguish two subtypes of sporadic VHL-Deficient clear cell renal carcinoma. J Exp Clin Cancer Res 281:435\u2013446. https:\/\/doi.org\/10.1016\/j.ccr.2008.10.016","journal-title":"J Exp Clin Cancer Res"},{"key":"8931_CR13","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1128\/MCB.25.13.5675-5686.2005","volume":"25","author":"RR Raval","year":"2005","unstructured":"Raval RR, Lau KW, Tran MGB, Sowter HM, Mandriota SJ, Li J-L, Pugh CW, Maxwell PH, Harris AL, Ratcliffe PJ (2005) Contrasting properties of Hypoxia-Inducible factor 1 (HIF-1) and HIF-2 in Von Hippel-Lindau-Associated Renal Cell Carcinoma. Mol Cell Biol 25:5675\u20135686. https:\/\/doi.org\/10.1128\/MCB.25.13.5675-5686.2005","journal-title":"Mol Cell Biol"},{"key":"8931_CR14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.eururo.2004.04.008","volume":"46","author":"V THEODOROPOULOS","year":"2004","unstructured":"THEODOROPOULOS V (2004) Hypoxia-inducible factor 1\u03b1 expression correlates with angiogenesis and unfavorable prognosis in Bladder Cancer. Eur Urol 46:200\u2013208. https:\/\/doi.org\/10.1016\/j.eururo.2004.04.008","journal-title":"Eur Urol"},{"key":"8931_CR15","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2018.4376","author":"X Yang","year":"2018","unstructured":"Yang X, Yin H, Zhang Y, Li X, Tong H, Zeng Y, Wang Q, He W (2018) Hypoxia-induced autophagy promotes gemcitabine resistance in human Bladder cancer cells through hypoxia-inducible factor 1\u03b1 activation. Int J Oncol. https:\/\/doi.org\/10.3892\/ijo.2018.4376","journal-title":"Int J Oncol"},{"key":"8931_CR16","first-page":"471","volume":"8","author":"T Onita","year":"2002","unstructured":"Onita T, Ji PG, Xuan JW, Sakai H, Kanetake H, Maxwell PH, Fong G-H, Gabril MY, Moussa M, Chin JL (2002) Hypoxia-induced, Perinecrotic expression of endothelial Per\u2013ARNT\u2013Sim domain Protein-1\/Hypoxia-inducible Factor-2\u03b1 correlates with Tumor Progression, Vascularization, and focal macrophage infiltration in bladder Cancer1. Clin Cancer Res 8:471\u2013480","journal-title":"Clin Cancer Res"},{"key":"8931_CR17","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.juro.2014.10.085","volume":"193","author":"WKB Ranasinghe","year":"2015","unstructured":"Ranasinghe WKB, Baldwin GS, Bolton D, Shulkes A, Ischia J, Patel O (2015) HIF1\u03b1 expression under Normoxia in Prostate Cancer\u2014 which pathways to target? J Urol 193:763\u2013770. https:\/\/doi.org\/10.1016\/j.juro.2014.10.085","journal-title":"J Urol"},{"key":"8931_CR18","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S1470-2045(08)70076-7","volume":"9","author":"R Vergis","year":"2008","unstructured":"Vergis R, Corbishley CM, Norman AR, Bartlett J, Jhavar S, Borre M, Heeboll S, Horwich A, Huddart R, Khoo V, Eeles R, Cooper C, Sydes M, Dearnaley D, Parker C (2008) Intrinsic markers of tumour hypoxia and angiogenesis in localised Prostate cancer and outcome of radical treatment: a retrospective analysis of two randomised radiotherapy trials and one surgical cohort study. Lancet Oncol 9:342\u2013351. https:\/\/doi.org\/10.1016\/S1470-2045(08)70076-7","journal-title":"Lancet Oncol"},{"key":"8931_CR19","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.ejca.2013.09.001","volume":"50","author":"A Fraga","year":"2014","unstructured":"Fraga A, Ribeiro R, Pr\u00edncipe P, Lobato C, Pina F, Maur\u00edcio J, Monteiro C, Sousa H, Calais da Silva F, Lopes C, Medeiros R (2014) The HIF1A functional genetic polymorphism at locus\u2009+\u20091772 associates with progression to metastatic Prostate cancer and refractoriness to hormonal castration. Eur J Cancer 50:359\u2013365. https:\/\/doi.org\/10.1016\/j.ejca.2013.09.001","journal-title":"Eur J Cancer"},{"key":"8931_CR20","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1172\/JCI35079","volume":"119","author":"S Nanni","year":"2009","unstructured":"Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, Mattiussi S, Colussi C, Lirangi V, Illi B, D\u2019Eletto M, Cianciulli AM, Gallucci M, De Carli P, Sentinelli S, Mottolese M, Carlini P, Strigari L, Finn S, Mueller E, Arcangeli G, Gaetano C, Capogrossi MC, Donnorso RP, Bacchetti S, Sacchi A, Pontecorvi A, Loda M, Farsetti A (2009) Endothelial NOS, estrogen receptor \u03b2, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human Prostate cancer. J Clin Invest 119:1093\u20131108. https:\/\/doi.org\/10.1172\/JCI35079","journal-title":"J Clin Invest"},{"key":"8931_CR21","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.4161\/cbt.4.11.2091","volume":"4","author":"CH Chau","year":"2005","unstructured":"Chau CH, Permenter MG, Steinberg SM, Retter AS, Dahut WL, Price DK, Figg IIW (2005) Polymorphism in the hypoxia-inducible factor 1\u03b1 gene may confer susceptibility to androgen-independent Prostate cancer. Cancer Biol Ther 4:1222\u20131225. https:\/\/doi.org\/10.4161\/cbt.4.11.2091","journal-title":"Cancer Biol Ther"},{"key":"8931_CR22","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1161\/ATVBAHA.108.181644","volume":"30","author":"GL Semenza","year":"2010","unstructured":"Semenza GL (2010) Vascular responses to Hypoxia and Ischemia. ATVB 30:648\u2013652. https:\/\/doi.org\/10.1161\/ATVBAHA.108.181644","journal-title":"ATVB"},{"key":"8931_CR23","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/joim.12016","volume":"273","author":"F Polet","year":"2013","unstructured":"Polet F, Feron O (2013) Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force. J Intern Med 273:156\u2013165. https:\/\/doi.org\/10.1111\/joim.12016","journal-title":"J Intern Med"},{"key":"8931_CR24","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/ncb3330","volume":"18","author":"EL LaGory","year":"2016","unstructured":"LaGory EL, Giaccia AJ (2016) The ever-expanding role of HIF in tumour and stromal biology. Nat Cell Biol 18:356\u2013365. https:\/\/doi.org\/10.1038\/ncb3330","journal-title":"Nat Cell Biol"},{"key":"8931_CR25","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/S0002-9440(10)64920-6","volume":"160","author":"S Morikawa","year":"2002","unstructured":"Morikawa S, Baluk P, Kaidoh T, Haskell A, Jain RK, McDonald DM (2002) Abnormalities in Pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160:985\u20131000","journal-title":"Am J Pathol"},{"key":"8931_CR26","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nature10144","volume":"473","author":"P Carmeliet","year":"2011","unstructured":"Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298\u2013307. https:\/\/doi.org\/10.1038\/nature10144","journal-title":"Nature"},{"key":"8931_CR27","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.3390\/cancers15041316","volume":"15","author":"S Mazumder","year":"2023","unstructured":"Mazumder S, Higgins PJ, Samarakoon R (2023) Downstream targets of VHL\/HIF-\u03b1 signaling in Renal Clear Cell Carcinoma Progression: mechanisms and therapeutic relevance. Cancers 15:1316. https:\/\/doi.org\/10.3390\/cancers15041316","journal-title":"Cancers"},{"key":"8931_CR28","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.ccr.2008.10.016","volume":"14","author":"JD Gordan","year":"2008","unstructured":"Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL (2008) HIF-\u03b1 effects on c-Myc Distinguish two subtypes of sporadic VHL-Deficient clear cell renal carcinoma. Cancer Cell 14:435\u2013446. https:\/\/doi.org\/10.1016\/j.ccr.2008.10.016","journal-title":"Cancer Cell"},{"key":"8931_CR29","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/nrc3183","volume":"12","author":"JD Gordan","year":"2012","unstructured":"Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, Greenberg RA, Flaherty KT, Rathmell WK, Keith B, Simon MC, Nathanson KL, Wu M, Huang Y, Chen T, Wang W, Yang S, Ye Z, Xi X, Zhu M, Chen Q, Liu X, Sun Q, Zhao X, Deng R, Wang Y, Huang J, Xu M, Yan J, Yu J, Keith B, Johnson RS, Simon MC, Roobol MJ, Carlsson SV, Mirzaei S, Paskeh MDA, Okina E, Gholami MH, Hushmandi K, Hashemi M, Kalu A, Zarrabi A, Nabavi N, Rabiee N, Sharifi E, Karimi-Maleh H, Ashrafizadeh M, Kumar AP, Wang Y (2012) HIF1\u03b1 and HIF2\u03b1: sibling rivalry in hypoxic tumour growth and progression. J Exp Clin Cancer Res 12:9\u201322. https:\/\/doi.org\/10.1038\/nrc3183","journal-title":"J Exp Clin Cancer Res"},{"key":"8931_CR30","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/onc.2011.305","volume":"31","author":"J Xu","year":"2012","unstructured":"Xu J, Wang B, Xu Y, Sun L, Tian W, Shukla D, Barod R, Grillari J, Grillari-Voglauer R, Maxwell PH, Esteban MA (2012) Epigenetic regulation of HIF-1\u03b1 in renal cancer cells involves HIF-1\u03b1\/2\u03b1 binding to a reverse hypoxia-response element. Oncogene 31:1065\u20131072. https:\/\/doi.org\/10.1038\/onc.2011.305","journal-title":"Oncogene"},{"key":"8931_CR31","doi-asserted-by":"publisher","first-page":"4111","DOI":"10.1038\/s41467-020-17873-3","volume":"11","author":"R Hoefflin","year":"2020","unstructured":"Hoefflin R, Harlander S, Sch\u00e4fer S, Metzger P, Kuo F, Sch\u00f6nenberger D, Adlesic M, Peighambari A, Seidel P, Chen C, Consenza-Contreras M, Jud A, Lahrmann B, Grabe N, Heide D, Uhl FM, Chan TA, Duyster J, Zeiser R, Schell C, Heikenwalder M, Schilling O, Hakimi AA, Boerries M, Frew IJ (2020) HIF-1\u03b1 and HIF-2\u03b1 differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice. Nat Commun 11:4111. https:\/\/doi.org\/10.1038\/s41467-020-17873-3","journal-title":"Nat Commun"},{"key":"8931_CR32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1093\/carcin\/bgl143","volume":"28","author":"T Shinojima","year":"2007","unstructured":"Shinojima T, Oya M, Takayanagi A, Mizuno R, Shimizu N, Murai M (2007) Renal cancer cells lacking hypoxia inducible factor (HIF)-1 expression maintain vascular endothelial growth factor expression through HIF-2. Carcinogenesis 28:529\u2013536. https:\/\/doi.org\/10.1093\/carcin\/bgl143","journal-title":"Carcinogenesis"},{"key":"8931_CR33","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1136\/jcp.2007.050666","volume":"61","author":"C-Y Chai","year":"2008","unstructured":"Chai C-Y, Chen W-T, Hung W-C, Kang W-Y, Huang Y-C, Su Y-C, Yang C-H (2008) Hypoxia-inducible factor-1 expression correlates with focal macrophage infiltration, angiogenesis and unfavourable prognosis in urothelial carcinoma. J Clin Pathol 61:658\u2013664. https:\/\/doi.org\/10.1136\/jcp.2007.050666","journal-title":"J Clin Pathol"},{"key":"8931_CR34","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.4161\/cc.6.11.4296","volume":"6","author":"F Koga","year":"2007","unstructured":"Koga F, Tsutsumi S, Neckers LM (2007) Low dose Geldanamycin inhibits hepatocyte growth factor- and Hypoxia-Stimulated Invasion of Cancer cells. Cell Cycle 6:1393\u20131402. https:\/\/doi.org\/10.4161\/cc.6.11.4296","journal-title":"Cell Cycle"},{"key":"8931_CR35","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/0008-5472.CAN-21-0403","volume":"82","author":"Y Xia","year":"2022","unstructured":"Xia Y, Wang X, Liu Y, Shapiro E, Lepor H, Tang M-S, Sun T-T, Wu X-R (2022) PKM2 is essential for Bladder Cancer growth and maintenance. Cancer Res 82:571\u2013585. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-0403","journal-title":"Cancer Res"},{"key":"8931_CR36","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1126\/science.275.5308.1943","volume":"275","author":"J Li","year":"1997","unstructured":"Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and Prostate Cancer. Science 275:1943\u20131947. https:\/\/doi.org\/10.1126\/science.275.5308.1943","journal-title":"Science"},{"key":"8931_CR37","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.cellsig.2007.07.025","volume":"19","author":"J Fang","year":"2007","unstructured":"Fang J, Ding M, Yang L, Liu L-Z, Jiang B-H (2007) PI3K\/PTEN\/AKT signaling regulates prostate Tumor angiogenesis. PLoS ONE 19:2487\u20132497. https:\/\/doi.org\/10.1016\/j.cellsig.2007.07.025","journal-title":"PLoS ONE"},{"key":"8931_CR38","doi-asserted-by":"publisher","first-page":"e50394","DOI":"10.1186\/s12943-015-0365-6","volume":"14","author":"X Ci","year":"2015","unstructured":"Ci X, Xing C, Zhang B, Zhang Z, Ni JJ, Zhou W, Dong J-T (2015) KLF5 inhibits angiogenesis in PTEN-deficient Prostate cancer by attenuating AKT activation and subsequent HIF1\u03b1 accumulation. Mol Cancer 14:e50394. https:\/\/doi.org\/10.1186\/s12943-015-0365-6","journal-title":"Mol Cancer"},{"key":"8931_CR39","doi-asserted-by":"publisher","first-page":"8635","DOI":"10.1158\/0008-5472.CAN-08-0917","volume":"68","author":"I Ader","year":"2008","unstructured":"Ader I, Brizuela L, Bouquerel P, Malavaud B, Cuvillier O (2008) Sphingosine kinase 1: a New Modulator of Hypoxia Inducible factor 1\u03b1 during Hypoxia in Human Cancer cells. Cancer Res 68:8635\u20138642. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-0917","journal-title":"Cancer Res"},{"key":"8931_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/j.1600-079X.2011.00865.x","volume":"51","author":"S-Y Cho","year":"2011","unstructured":"Cho S-Y, Lee H-J, Jeong S-J, Lee H-J, Kim H-S, Chen CY, Lee E-O, Kim S-H (2011) Sphingosine kinase 1 pathway is involved in melatonin-induced HIF-1\u03b1 inactivation in hypoxic PC-3 Prostate cancer cells. J Pineal Res 51:87\u201393. https:\/\/doi.org\/10.1111\/j.1600-079X.2011.00865.x","journal-title":"J Pineal Res"},{"key":"8931_CR41","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/carcin\/bgl085","volume":"28","author":"Q Zhou","year":"2007","unstructured":"Zhou Q, Liu L-Z, Fu B, Hu X, Shi X, Fang J, Jiang B-H (2007) Reactive oxygen species regulate insulin-induced VEGF and HIF-1 expression through the activation of p70S6K1 in human Prostate cancer cells. Carcinogenesis 28:28\u201337. https:\/\/doi.org\/10.1093\/carcin\/bgl085","journal-title":"Carcinogenesis"},{"key":"8931_CR42","doi-asserted-by":"publisher","first-page":"3355","DOI":"10.1007\/s00018-015-1891-5","volume":"72","author":"AB Fern\u00e1ndez-Mart\u00ednez","year":"2015","unstructured":"Fern\u00e1ndez-Mart\u00ednez AB, Lucio-Caza\u00f1a J (2015) Intracellular EP2 prostanoid receptor promotes cancer-related phenotypes in PC3 cells. Cell Mol Life Sci 72:3355\u20133373. https:\/\/doi.org\/10.1007\/s00018-015-1891-5","journal-title":"Cell Mol Life Sci"},{"key":"8931_CR43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.bbcan.2018.07.002","volume":"1870","author":"D Samanta","year":"2018","unstructured":"Samanta D, Semenza GL (2018) Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors. Biochimica et Biophysica Acta (BBA) -. Reviews on Cancer 1870:15\u201322. https:\/\/doi.org\/10.1016\/j.bbcan.2018.07.002","journal-title":"Reviews on Cancer"},{"key":"8931_CR44","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1016\/j.ijbiomac.2022.10.014","volume":"222","author":"Y Luo","year":"2022","unstructured":"Luo Y, Yang Z, Yu Y, Zhang P (2022) HIF1\u03b1 lactylation enhances KIAA1199 transcription to promote angiogenesis and vasculogenic mimicry in Prostate cancer. Int J Biol Macromol 222:2225\u20132243. https:\/\/doi.org\/10.1016\/j.ijbiomac.2022.10.014","journal-title":"Int J Biol Macromol"},{"key":"8931_CR45","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/j.celrep.2016.04.028","volume":"15","author":"L Pisarsky","year":"2016","unstructured":"Pisarsky L, Bill R, Fagiani E, Dimeloe S, Goosen RW, Hagmann J, Hess C, Christofori G (2016) Targeting metabolic symbiosis to Overcome Resistance to anti-angiogenic therapy. Cell Rep 15:1161\u20131174. https:\/\/doi.org\/10.1016\/j.celrep.2016.04.028","journal-title":"Cell Rep"},{"key":"8931_CR46","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.cell.2010.01.045","volume":"140","author":"T Tammela","year":"2010","unstructured":"Tammela T, Alitalo K (2010) Lymphangiogenesis: Molecular mechanisms and Future Promise. Cell 140:460\u2013476. https:\/\/doi.org\/10.1016\/j.cell.2010.01.045","journal-title":"Cell"},{"key":"8931_CR47","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1182\/blood-2007-08-106302","volume":"112","author":"A Ny","year":"2008","unstructured":"Ny A, Koch M, Vandevelde W, Schneider M, Fischer C, Diez-Juan A, Neven E, Geudens I, Maity S, Moons L, Plaisance S, Lambrechts D, Carmeliet P, Dewerchin M (2008) Role of VEGF-D and VEGFR-3 in developmental lymphangiogenesis, a chemicogenetic study in Xenopus tadpoles. Blood 112:1740\u20131749. https:\/\/doi.org\/10.1182\/blood-2007-08-106302","journal-title":"Blood"},{"key":"8931_CR48","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.canlet.2013.12.001","volume":"346","author":"R-C Ji","year":"2014","unstructured":"Ji R-C, Li L, Ameri AH, Wang S, Jansson KH, Casey OM, Yang Q, Beshiri ML, Fang L, Lake RG, Agarwal S, Alilin AN, Xu W, Yin J, Kelly K (2014) Hypoxia and lymphangiogenesis in Tumor microenvironment and Metastasis. Cancer Lett 346:6\u201316. https:\/\/doi.org\/10.1016\/j.canlet.2013.12.001","journal-title":"Cancer Lett"},{"key":"8931_CR49","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1158\/0008-5472.CAN-08-1879","volume":"69","author":"F Spinella","year":"2009","unstructured":"Spinella F, Garrafa E, Di Castro V, Rosan\u00f2 L, Nicotra MR, Caruso A, Natali PG, Bagnato A (2009) Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade. Cancer Res 69:2669\u20132676. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-1879","journal-title":"Cancer Res"},{"key":"8931_CR50","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1182\/blood-2008-12-196840","volume":"115","author":"MJ Flister","year":"2010","unstructured":"Flister MJ, Wilber A, Hall KL, Iwata C, Miyazono K, Nisato RE, Pepper MS, Zawieja DC, Ran S (2010) Inflammation induces lymphangiogenesis through up-regulation of VEGFR-3 mediated by NF-\u03baB and Prox1. Blood 115:418\u2013429. https:\/\/doi.org\/10.1182\/blood-2008-12-196840","journal-title":"Blood"},{"key":"8931_CR51","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.addr.2016.01.020","volume":"99","author":"Y Yoshimatsu","year":"2016","unstructured":"Yoshimatsu Y, Miyazaki H, Watabe T (2016) Roles of signaling and transcriptional networks in pathological lymphangiogenesis. Adv Drug Deliv Rev 99:161\u2013171. https:\/\/doi.org\/10.1016\/j.addr.2016.01.020","journal-title":"Adv Drug Deliv Rev"},{"key":"8931_CR52","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","volume":"141","author":"B-Z Qian","year":"2010","unstructured":"Qian B-Z, Pollard JW (2010) Macrophage diversity enhances Tumor Progression and Metastasis. Cell 141:39\u201351. https:\/\/doi.org\/10.1016\/j.cell.2010.03.014","journal-title":"Cell"},{"key":"8931_CR53","doi-asserted-by":"publisher","first-page":"764","DOI":"10.4049\/jimmunol.0903421","volume":"186","author":"T Gaber","year":"2011","unstructured":"Gaber T, Schellmann S, Erekul KB, Fangradt M, Tykwinska K, Hahne M, Maschmeyer P, Wagegg M, Stahn C, Kolar P, Dziurla R, L\u00f6hning M, Burmester G-R, Buttgereit F (2011) Macrophage Migration Inhibitory factor counterregulates dexamethasone-mediated suppression of Hypoxia-Inducible Factor-1\u03b1 function and differentially influences Human CD4\u2009+\u2009T cell proliferation under Hypoxia. J Immunol 186:764\u2013774. https:\/\/doi.org\/10.4049\/jimmunol.0903421","journal-title":"J Immunol"},{"key":"8931_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1096\/fj.03-0329fje","volume":"17","author":"Y-J Jung","year":"2003","unstructured":"Jung Y-J, Isaacs JS, Lee S, Trepel J, Neckers L (2003) IL-1\u03b2 mediated up\u2010regulation of HIF\u2010l\u03b1 via an NFkB\/COX\u20102 pathway identifies HIF\u20101 as a critical link between inflammation and oncogenesis. FASEB j 17:1\u201322. https:\/\/doi.org\/10.1096\/fj.03-0329fje","journal-title":"FASEB j"},{"key":"8931_CR55","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1016\/j.ajpath.2012.12.003","volume":"182","author":"P Baluk","year":"2013","unstructured":"Baluk P, Hogmalm A, Bry M, Alitalo K, Bry K, McDonald DM (2013) Transgenic overexpression of Interleukin-1\u03b2 induces persistent Lymphangiogenesis but not angiogenesis in Mouse Airways. Am J Pathol 182:1434\u20131447. https:\/\/doi.org\/10.1016\/j.ajpath.2012.12.003","journal-title":"Am J Pathol"},{"key":"8931_CR56","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1158\/0008-5472.can-03-1301","volume":"64","author":"J-L Su","year":"2004","unstructured":"Su J-L, Shih J-Y, Yen M-L, Jeng Y-M, Chang C-C, Hsieh C-Y, Wei L-H, Yang P-C, Kuo M-L (2004) Cyclooxygenase-2 induces EP1- and HER-2\/Neu-Dependent vascular endothelial growth Factor-C Up-Regulation. Cancer Res 64:554\u2013564. https:\/\/doi.org\/10.1158\/0008-5472.can-03-1301","journal-title":"Cancer Res"},{"key":"8931_CR57","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/nrc3677","volume":"14","author":"SA Stacker","year":"2014","unstructured":"Stacker SA, Williams SP, Karnezis T, Shayan R, Fox SB, Achen MG (2014) Lymphangiogenesis and lymphatic vessel remodelling in cancer. Nat Rev Cancer 14:159\u2013172. https:\/\/doi.org\/10.1038\/nrc3677","journal-title":"Nat Rev Cancer"},{"key":"8931_CR58","doi-asserted-by":"publisher","first-page":"5387","DOI":"10.1158\/1078-0432.CCR-12-0708","volume":"18","author":"W Zhuo","year":"2012","unstructured":"Zhuo W, Jia L, Song N, Lu X, Ding Y, Wang X, Song X, Fu Y, Luo Y (2012) The CXCL12\u2013CXCR4 chemokine pathway: a Novel Axis regulates Lymphangiogenesis. Clin Cancer Res 18:5387\u20135398. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0708","journal-title":"Clin Cancer Res"},{"key":"8931_CR59","doi-asserted-by":"publisher","first-page":"4499","DOI":"10.1038\/onc.2011.602","volume":"31","author":"A Alitalo","year":"2012","unstructured":"Alitalo A, Detmar M (2012) Interaction of Tumor cells and lymphatic vessels in cancer progression. Oncogene 31:4499\u20134508. https:\/\/doi.org\/10.1038\/onc.2011.602","journal-title":"Oncogene"},{"key":"8931_CR60","doi-asserted-by":"publisher","first-page":"661","DOI":"10.7150\/thno.27794","volume":"9","author":"PD Ndiaye","year":"2019","unstructured":"Ndiaye PD, Dufies M, Giuliano S, Douguet L, Gr\u00e9pin R, Durivault J, Lenormand P, Glisse N, Mintcheva J, Vouret-Craviari V, Mograbi B, Wurmser M, Ambrosetti D, Rioux-Leclercq N, Maire P, Pag\u00e8s G (2019) VEGFC acts as a double-edged sword in renal cell carcinoma aggressiveness. Theranostics 9:661\u2013675. https:\/\/doi.org\/10.7150\/thno.27794","journal-title":"Theranostics"},{"key":"8931_CR61","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.celrep.2012.01.005","volume":"1","author":"AW Lund","year":"2012","unstructured":"Lund AW, Duraes FV, Hirosue S, Raghavan VR, Nembrini C, Thomas SN, Issa A, Hugues S, Swartz MA (2012) VEGF-C promotes Immune Tolerance in B16 Melanomas and Cross-presentation of Tumor Antigen by Lymph Node Lymphatics. Cell Rep 1:191\u2013199. https:\/\/doi.org\/10.1016\/j.celrep.2012.01.005","journal-title":"Cell Rep"},{"key":"8931_CR62","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/j.ajpath.2017.04.007","volume":"187","author":"Y-C Guo","year":"2017","unstructured":"Guo Y-C, Zhang M, Wang F-X, Pei G-C, Sun F, Zhang Y, He X, Wang Y, Song J, Zhu F-M, Pandupuspitasari NS, Liu J, Huang K, Yang P, Xiong F, Zhang S, Yu Q, Yao Y, Wang C-Y (2017) Macrophages regulate unilateral Ureteral obstruction-Induced Renal Lymphangiogenesis through C-C motif chemokine receptor 2\u2013Dependent phosphatidylinositol 3-Kinase-AKT\u2013Mechanistic target of Rapamycin Signaling and Hypoxia-Inducible Factor-1\u03b1\/Vascular endothelial growth Factor-C expression. Am J Pathol 187:1736\u20131749. https:\/\/doi.org\/10.1016\/j.ajpath.2017.04.007","journal-title":"Am J Pathol"},{"key":"8931_CR63","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.celrep.2013.12.011","volume":"6","author":"F Morfoisse","year":"2014","unstructured":"Morfoisse F, Kuchnio A, Frainay C, Gomez-Brouchet A, Delisle M-B, Marzi S, Helfer A-C, Hantelys F, Pujol F, Guillermet-Guibert J, Bousquet C, Dewerchin M, Pyronnet S, Prats A-C, Carmeliet P, Garmy-Susini B (2014) Hypoxia induces VEGF-C expression in metastatic Tumor cells via a HIF-1\u03b1-Independent translation-mediated mechanism. Cell Rep 6:155\u2013167. https:\/\/doi.org\/10.1016\/j.celrep.2013.12.011","journal-title":"Cell Rep"},{"key":"8931_CR64","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06.081","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson NM, Simon MC (2020) The Tumor microenvironment. Proc Natl Acad Sci USA 30:R921\u2013R925. https:\/\/doi.org\/10.1016\/j.cub.2020.06.081","journal-title":"Proc Natl Acad Sci USA"},{"key":"8931_CR65","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","volume":"211","author":"MZ Noman","year":"2014","unstructured":"Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S, Mimura K, Kono K, Takahashi A, Kawaguchi Y, Fujii H (2014) PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211:781\u2013790. https:\/\/doi.org\/10.1084\/jem.20131916","journal-title":"J Exp Med"},{"key":"8931_CR66","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nrc.2016.54","volume":"16","author":"C Engblom","year":"2016","unstructured":"Engblom C, Pfirschke C, Pittet MJ (2016) The role of myeloid cells in cancer therapies. Nat Rev Cancer 16:447\u2013462. https:\/\/doi.org\/10.1038\/nrc.2016.54","journal-title":"Nat Rev Cancer"},{"key":"8931_CR67","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/nature10169","volume":"475","author":"A Facciabene","year":"2011","unstructured":"Facciabene A, Peng X, Hagemann IS, Balint K, Barchetti A, Wang L-P, Gimotty PA, Gilks CB, Lal P, Zhang L, Coukos G (2011) Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells. Nature 475:226\u2013230. https:\/\/doi.org\/10.1038\/nature10169","journal-title":"Nature"},{"key":"8931_CR68","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1146\/annurev-physiol-020518-114700","volume":"81","author":"JD Martin","year":"2019","unstructured":"Martin JD, Seano G, Jain RK (2019) Normalizing function of Tumor vessels: Progress, opportunities, and challenges. Annu Rev Physiol 81:505\u2013534. https:\/\/doi.org\/10.1146\/annurev-physiol-020518-114700","journal-title":"Annu Rev Physiol"},{"key":"8931_CR69","doi-asserted-by":"publisher","first-page":"15101","DOI":"10.1073\/pnas.1213353109","volume":"109","author":"T Stylianopoulos","year":"2012","unstructured":"Stylianopoulos T, Martin JD, Chauhan VP, Jain SR, Diop-Frimpong B, Bardeesy N, Smith BL, Ferrone CR, Hornicek FJ, Boucher Y, Munn LL, Jain RK (2012) Causes, consequences, and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci USA 109:15101\u201315108. https:\/\/doi.org\/10.1073\/pnas.1213353109","journal-title":"Proc Natl Acad Sci USA"},{"key":"8931_CR70","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","volume":"15","author":"KA Khan","year":"2018","unstructured":"Khan KA, Kerbel RS (2018) Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol 15:310\u2013324. https:\/\/doi.org\/10.1038\/nrclinonc.2018.9","journal-title":"Nat Rev Clin Oncol"},{"key":"8931_CR71","doi-asserted-by":"publisher","first-page":"20212","DOI":"10.1073\/pnas.1320318110","volume":"110","author":"C Feig","year":"2013","unstructured":"Feig C, Jones JO, Kraman M, Wells RJB, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL, Teichmann SA, Janowitz T, Jodrell DI, Tuveson DA, Fearon DT (2013) Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti\u2013PD-L1 immunotherapy in Pancreatic cancer. Proc Natl Acad Sci USA 110:20212\u201320217. https:\/\/doi.org\/10.1073\/pnas.1320318110","journal-title":"Proc Natl Acad Sci USA"},{"key":"8931_CR72","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1084\/jem.20140692","volume":"211","author":"D \u00d6hlund","year":"2014","unstructured":"\u00d6hlund D, Elyada E, Tuveson D (2014) Fibroblast heterogeneity in the cancer wound. J Exp Med 211:1503\u20131523. https:\/\/doi.org\/10.1084\/jem.20140692","journal-title":"J Exp Med"},{"key":"8931_CR73","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.trecan.2018.02.005","volume":"4","author":"T Stylianopoulos","year":"2018","unstructured":"Stylianopoulos T, Munn LL, Jain RK (2018) Reengineering the physical microenvironment of tumors to Improve Drug Delivery and Efficacy: from Mathematical modeling to bench to Bedside. Trends Cancer 4:292\u2013319. https:\/\/doi.org\/10.1016\/j.trecan.2018.02.005","journal-title":"Trends Cancer"},{"key":"8931_CR74","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/nnano.2012.45","volume":"7","author":"VP Chauhan","year":"2012","unstructured":"Chauhan VP, Stylianopoulos T, Martin JD, Popovi\u0107 Z, Chen O, Kamoun WS, Bawendi MG, Fukumura D, Jain RK (2012) Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotech 7:383\u2013388. https:\/\/doi.org\/10.1038\/nnano.2012.45","journal-title":"Nat Nanotech"},{"key":"8931_CR75","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1084\/jem.20140559","volume":"212","author":"T Voron","year":"2015","unstructured":"Voron T, Colussi O, Marcheteau E, Pernot S, Nizard M, Pointet A-L, Latreche S, Bergaya S, Benhamouda N, Tanchot C, Stockmann C, Combe P, Berger A, Zinzindohoue F, Yagita H, Tartour E, Taieb J, Terme M, Kusmartsev S, Eruslanov E, K\u00fcbler H, Tseng T, Sakai Y, Su Z, Kaliberov S, Heiser A, Rosser C, Dahm P, Siemann D, Vieweg J (2015) VEGF-A modulates expression of inhibitory checkpoints on CD8\u2009+\u2009T cells in tumors. J Exp Med 212:139\u2013148. https:\/\/doi.org\/10.1084\/jem.20140559","journal-title":"J Exp Med"},{"key":"8931_CR76","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/bjc.2012.468","volume":"107","author":"NG Gavalas","year":"2012","unstructured":"Gavalas NG, Tsiatas M, Tsitsilonis O, Politi E, Ioannou K, Ziogas AC, Rodolakis A, Vlahos G, Thomakos N, Haidopoulos D, Terpos E, Antsaklis A, Dimopoulos MA, Bamias A (2012) VEGF directly suppresses activation of T cells from Ascites secondary to Ovarian cancer via VEGF receptor type 2. Br J Cancer 107:1869\u20131875. https:\/\/doi.org\/10.1038\/bjc.2012.468","journal-title":"Br J Cancer"},{"key":"8931_CR77","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s00262-006-0234-7","volume":"56","author":"K Mimura","year":"2007","unstructured":"Mimura K, Kono K, Takahashi A, Kawaguchi Y, Fujii H (2007) Vascular endothelial growth factor inhibits the function of human mature dendritic cells mediated by VEGF receptor-2. Cancer Immunol Immunother 56:761\u2013770. https:\/\/doi.org\/10.1007\/s00262-006-0234-7","journal-title":"Cancer Immunol Immunother"},{"key":"8931_CR78","doi-asserted-by":"publisher","first-page":"4470","DOI":"10.1073\/pnas.1525349113","volume":"113","author":"TE Peterson","year":"2016","unstructured":"Peterson TE, Kirkpatrick ND, Huang Y, Farrar CT, Marijt KA, Kloepper J, Datta M, Amoozgar Z, Seano G, Jung K, Kamoun WS, Vardam T, Snuderl M, Goveia J, Chatterjee S, Batista A, Muzikansky A, Leow CC, Xu L, Batchelor TT, Duda DG, Fukumura D, Jain RK (2016) Dual inhibition of Ang-2 and VEGF receptors normalizes Tumor vasculature and prolongs survival in glioblastoma by altering macrophages. Proc Natl Acad Sci USA 113:4470\u20134475. https:\/\/doi.org\/10.1073\/pnas.1525349113","journal-title":"Proc Natl Acad Sci USA"},{"key":"8931_CR79","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1084\/jem.20111497","volume":"209","author":"W Hansen","year":"2012","unstructured":"Hansen W, Hutzler M, Abel S, Alter C, Stockmann C, Kliche S, Albert J, Sparwasser T, Sakaguchi S, Westendorf AM, Schadendorf D, Buer J, Helfrich I (2012) Neuropilin 1 deficiency on CD4\u2009+\u2009Foxp3\u2009+\u2009regulatory T cells impairs mouse Melanoma growth. Proc Natl Acad Sci USA 209:2001\u20132016. https:\/\/doi.org\/10.1084\/jem.20111497","journal-title":"Proc Natl Acad Sci USA"},{"key":"8931_CR80","doi-asserted-by":"publisher","first-page":"346","DOI":"10.4049\/jimmunol.181.1.346","volume":"181","author":"S Kusmartsev","year":"2008","unstructured":"Kusmartsev S, Eruslanov E, K\u00fcbler H, Tseng T, Sakai Y, Su Z, Kaliberov S, Heiser A, Rosser C, Dahm P, Siemann D, Vieweg J (2008) Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to Tumor-Induced Immune suppression in renal cell carcinoma. J Immunol 181:346\u2013353. https:\/\/doi.org\/10.4049\/jimmunol.181.1.346","journal-title":"J Immunol"},{"key":"8931_CR81","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1038\/s41388-022-02423-6","volume":"41","author":"J Jiang","year":"2022","unstructured":"Jiang J, Chen S, Tsou T, McGinnis CS, Khazaei T, Zhu Q, Park JH, Strazhnik I-M, Hanna J, Chow ED, Sivak DA, Gartner ZJ, Thomson M, Wang X, Brea L, Lu X, Gritsina G, Park SH, Xie W, Zhao JC, Yu J (2022) FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A. Oncogene 41:4259\u20134270. https:\/\/doi.org\/10.1038\/s41388-022-02423-6","journal-title":"Oncogene"},{"key":"8931_CR82","doi-asserted-by":"publisher","first-page":"e106224","DOI":"10.1371\/journal.pone.0106224","volume":"9","author":"DM Hutt","year":"2014","unstructured":"Hutt DM, Roth DM, Vignaud H, Cullin C, Bouchecareilh M (2014) The histone deacetylase inhibitor, Vorinostat, Represses Hypoxia Inducible Factor 1 alpha expression through translational inhibition. PLoS ONE 9:e106224. https:\/\/doi.org\/10.1371\/journal.pone.0106224","journal-title":"PLoS ONE"},{"key":"8931_CR83","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","volume":"385","author":"E Jonasch","year":"2021","unstructured":"Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R, MK-6482-004 Investigators (2021) Belzutifan for Renal Cell Carcinoma in Von Hippel\u2013Lindau Disease. N Engl J Med 385:2036\u20132046. https:\/\/doi.org\/10.1056\/NEJMoa2103425","journal-title":"N Engl J Med"},{"key":"8931_CR84","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1007\/s00280-016-3134-3","volume":"78","author":"MW Saif","year":"2016","unstructured":"Saif MW, Knost JA, Chiorean EG, Kambhampati SRP, Yu D, Pytowski B, Qin A, Kauh JS, O\u2019Neil BH (2016) Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856\/IMC-3C5 in patients with advanced and refractory solid tumors and advanced Colorectal cancer. Cancer Chemother Pharmacol 78:815\u2013824. https:\/\/doi.org\/10.1007\/s00280-016-3134-3","journal-title":"Cancer Chemother Pharmacol"},{"key":"8931_CR85","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1517\/13543784.2015.1041588","volume":"24","author":"CR Mazzola","year":"2015","unstructured":"Mazzola CR, Chin J (2015) Targeting the VEGF pathway in metastatic Bladder cancer. Cell Death Dis 24:913\u2013927. https:\/\/doi.org\/10.1517\/13543784.2015.1041588","journal-title":"Cell Death Dis"},{"key":"8931_CR86","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1200\/JCO.21.00286","volume":"39","author":"JE Rosenberg","year":"2021","unstructured":"Rosenberg JE, Ballman KA, Halabi S, Atherton PJ, Mortazavi A, Sweeney C, Stadler WM, Teply BA, Picus J, Tagawa ST, Katragadda S, Vaena D, Misleh J, Hoimes C, Plimack ER, Flaig TW, Dreicer R, Bajorin D, Hahn O, Small EJ, Morris MJ (2021) Randomized Phase III Trial of Gemcitabine and Cisplatin with Bevacizumab or Placebo in patients with Advanced Urothelial Carcinoma: results of CALGB 90601 (Alliance). JCO 39:2486\u20132496. https:\/\/doi.org\/10.1200\/JCO.21.00286","journal-title":"JCO"},{"key":"8931_CR87","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1038\/s43018-021-00237-1","volume":"2","author":"Y Qiao","year":"2021","unstructured":"Qiao Y, Choi JE, Tien JC, Simko SA, Rajendiran T, Vo JN, Delekta AD, Wang L, Xiao L, Hodge NB, Desai P, Mendoza S, Juckette K, Xu A, Soni T, Su F, Wang R, Cao X, Yu J, Kryczek I, Wang X-M, Wang X, Siddiqui J, Wang Z, Bernard A, Fernandez-Salas E, Navone NM, Ellison SJ, Ding K, Eskelinen E-L, Heath EI, Klionsky DJ, Zou W, Chinnaiyan AM (2021) Autophagy inhibition by targeting PIKfyve potentiates response to immune checkpoint blockade in Prostate cancer. Nat Cancer 2:978\u2013993. https:\/\/doi.org\/10.1038\/s43018-021-00237-1","journal-title":"Nat Cancer"},{"key":"8931_CR88","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ccr.2004.08.034","volume":"6","author":"R Cao","year":"2004","unstructured":"Cao R, Bj\u00f6rndahl MA, Religa P, Clasper S, Garvin S, Galter D, Meister B, Ikomi F, Tritsaris K, Dissing S, Ohhashi T, Jackson DG, Cao Y (2004) PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic Metastasis. Cancer Cell 6:333\u2013345. https:\/\/doi.org\/10.1016\/j.ccr.2004.08.034","journal-title":"Cancer Cell"},{"key":"8931_CR89","doi-asserted-by":"publisher","first-page":"E2707","DOI":"10.1073\/pnas.1214019109","volume":"109","author":"L Schito","year":"2012","unstructured":"Schito L, Rey S, Tafani M, Zhang H, Wong CC-L, Russo A, Russo MA, Semenza GL (2012) Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic Metastasis of hypoxic Breast cancer cells. Proc Natl Acad Sci USA 109:E2707\u20132716. https:\/\/doi.org\/10.1073\/pnas.1214019109","journal-title":"Proc Natl Acad Sci USA"},{"key":"8931_CR90","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, Bamias A, Lebret T, Shariat SF, Park SH, Ye D, Agerbaek M, Enting D, McDermott R, Gajate P, Peer A, Milowsky MI, Nosov A, Neif Antonio J, Tupikowski K, Toms L, Fischer BS, Qureshi A, Collette S, Unsal-Kacmaz K, Broughton E, Zardavas D, Koon HB, Galsky MD (2021) Adjuvant Nivolumab versus Placebo in muscle-invasive Urothelial Carcinoma. N Engl J Med 384:2102\u20132114. https:\/\/doi.org\/10.1056\/NEJMoa2034442","journal-title":"N Engl J Med"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08931-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-023-08931-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-023-08931-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T21:03:42Z","timestamp":1738703022000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-023-08931-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["8931"],"URL":"https:\/\/doi.org\/10.1007\/s11033-023-08931-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]},"assertion":[{"value":"22 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}